Cavion Inc. (Charlottesville, Va.) said CX-8998 missed the primary endpoint in the Phase II T-CALM trial to treat moderate to severe essential tremor. Despite the miss, the company plans to start a Phase III trial by 4Q19 of the compound in the indication that will use a different primary endpoint than that of the Phase II trial. CX-8998 is a calcium channel T-type blocker.

On the Phase II trial's primary endpoint, CX-8998 failed to improve tremor severity from baseline to day 28...